Alliteration: CAMP4, Curon, Curium, CDKs, and cell therapies

Week 41 Deals (2024)

October 04, 2024

Acquisition of next-generation CDK inhibitors portfolio for breast cancer

Structure: Acquisition of portfolio
Date Announced: September 30, 2024
Total Deal Value: $850M upfront + undisclosed milestone payments
Upfront Cash: $850M
Other Terms: Genentech assumes global development, manufacturing, and commercialization responsibility. Regor to complete two ongoing Phase 1 trials.

Strategic research and licensing agreement for next-generation ex vivo T-cell therapies

Structure: Research collaboration and license agreement
Date Announced: September 30, 2024
Total Deal Value: >$3.5B potential + royalties
Upfront Cash: $55M
Equity Investment: $55M
Total Milestones: $3.5B ($1.4B development, >$2.1B commercialization)
Royalties: Undisclosed tiered royalties
Other Terms: Prime Medicine to design Prime Editor reagents for select targets; BMS responsible for development, manufacturing, and commercialization

Acquisition of B-cell depletion therapy CN201

Structure: Asset acquisition
Date Announced: October 1, 2024
Total Deal Value: $750M upfront
Upfront Cash: $750M
Other Terms: Merck acquires full global rights to CN201 (currently in Phase 1 and Phase 1b/2 trials)

Strategic partnership for prostate cancer therapies in Japan

Structure: Strategic Partnership
Date Announced: October 1, 2024
Terms: Co-development of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T
Other Terms: PDRadiopharma handles regulatory filing, manufacturing, and commercialization in Japan; Curium supports technology transfer

Research collaboration for RNA-targeting medicines

Structure: Research collaboration
Date Announced: October 1, 2024
Terms: Undisclosed upfront payment + milestones + tiered royalties
Other Terms: BioMarin gains rights to select two targets from CAMP4's platform